Semi-OT:BOTHELL, Wash.-(BW)-Sept.7-Northwest Biotherapeutics, Inc. announced today that it has commenced operations in its new, 40,000 square feet corporate headquarters, laboratory and state-of-the-art cell processing facility in Bothell, Washington.
"We are very pleased that our new location was completed on time and within budget," commented Charles Jacob III, the Senior Project Manager for Northwest Biotherapeutics responsible for constructing the new facility. "This represents the successful culmination of two year's work and it immediately positions us with sufficient GMP manufacturing capacity for large Phase III clinical trials to assess our immunotherapy, DCVax(TM), for the treatment of prostate and other cancers". Mr. Jacob also noted that the new facility includes 5,000 square feet of expansion space for future growth.
The new facility is the first segment to be completed of a 112,000 square feet commercial complex being developed by Nexus Canyon Park LLC, a California Limited Liability Corporation affiliated with Nexus Properties, Inc. Northwest Biotherapeutics' facility was designed by CNA Architecture Inc. of Bellevue, Washington and was constructed by DPR Construction, Inc. of Seattle, Washington and Advanced Technology Construction LLC of Renton, Washington.
Northwest Biotherapeutics, Inc. is a privately held company founded in 1996 to develop and commercialize products and services to improve care for prostate and other cancer patients. It is currently sponsoring a 60 patient clinical trial at M.D. Anderson Cancer Center in Houston and the University of California, Los Angeles (UCLA) to evaluate the safety and efficacy of its immunotherapy for late stage prostate cancer patients with no remaining treatment options. In addition to prostate cancer, Northwest Biotherapeutics is developing its proprietary immunotherapy platform for application to a number of other life-threatening forms of cancer. For additional information on Northwest Biotherapeutics, visit the Company's web site at www.nwbio.com.
Here is a link to Northwest Bio's PI trial using PSMA:
Phase I Clinical Trial Of Recombinant Prostate Specific Membrane Antigen (rPSMA)-Loaded Mature Autologous Dendritic Cells (CaPVax) For The Treatment Of Metastatic Hormone Refractory Prostate Cancer
utm-notes-db2.mdacc.tmc.edu
Jim |
